

AD _____

Award Number: DAMD17-01-1-0639

TITLE: Promotion of Breast Cancer Growth Within Bone by the
C-terminal Hexapeptide Enzymatically Derived From
Osteocalcin, a Bone Matrix Protein

PRINCIPAL INVESTIGATOR: Satoru Kenneth Nishimoto, Ph.D.

CONTRACTING ORGANIZATION: The University of Tennessee
Memphis, Tennessee 38163

REPORT DATE: August 2002

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20030701 182

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

| | | | | |
|--|---|--|--|---------------------------------|
| 1. AGENCY USE ONLY (Leave blank) | | 2. REPORT DATE August 2002 | 3. REPORT TYPE AND DATES COVERED Final (16 Jul 01 - 15 Jul 02) | |
| 4. TITLE AND SUBTITLE Promotion of Breast Cancer Growth Within Bone by the C-terminal Hexapeptide Enzymatically Derived From Osteocalcin, a Bone Matrix Protein | | | 5. FUNDING NUMBERS DAMD17-01-1-0639 | |
| 6. AUTHOR(S) Satoru Kenneth Nishimoto, Ph.D. | | | | |
| 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) The University of Tennessee Memphis, Tennessee 38163 E-Mail: snishimoto@utmem.edu | | | 8. PERFORMING ORGANIZATION REPORT NUMBER | |
| 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 | | | 10. SPONSORING / MONITORING AGENCY REPORT NUMBER | |
| 11. SUPPLEMENTARY NOTES | | | | |
| 12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited | | | | 12b. DISTRIBUTION CODE |
| 13. Abstract (Maximum 200 Words) (abstract should contain no proprietary or confidential information) <p>Plasmin enzymatically produces an Osteocalcin-derived C-terminal Hexapeptide from bone matrix which promotes the growth of human osteosarcoma cells by blocking the action of the hormone oxytocin.</p> <p>We hypothesize that the C-terminal Hexapeptide promotes the growth of breast cancer cells in bone. Breast cancer cells that are growth inhibited by oxytocin may be growth stimulated in bone where abundant C-terminal Hexapeptide is present. Growth stimulation in bone would enhance the likelihood of bone metastasis by breast cancer cells.</p> <p>Our first objective was to determine the affect of C-terminal Hexapeptide on the growth of MDA-MB-231 breast cancer cells inhibited by oxytocin, as published by others. Oxytocin (10^{-5} M) inhibited growth but this is not in agreement with published results. We have obtained a 1-year no cost extension to: examine alternate sources and forms of oxytocin and try cAMP and PGE₂ assays to see if biological effectiveness of oxytocin is achieved. Once an effective oxytocin and cell assay is established we will characterize the effects of hexapeptide on breast cancer cells.</p> <p>Counteracting the metastasis of breast cancer to bone could enhance patient survival. Understanding the mechanisms that enable breast cancer cells to metastasize, survive, and grow in bone are vital to alter the process. The experiments should provide new information on the growth stimulatory environment of bone, and contribute to the understanding of bone-seeking breast cancers. The knowledge will be useful for developing strategies to counteract the spread of breast cancer to bone.</p> | | | | |
| 14. SUBJECT TERMS bone metastasis, osteocalcin, oxytocin, breast carcinoma, breast cancer | | | | 15. NUMBER OF PAGES 5 |
| | | | | 16. PRICE CODE |
| 17. SECURITY CLASSIFICATION OF REPORT Unclassified | 18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified | 19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified | 20. LIMITATION OF ABSTRACT Unlimited | |

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

Table of Contents

| | |
|-----------------------------------|---|
| Cover..... | 1 |
| SF 298..... | 2 |
| Table of Contents..... | 3 |
| Introduction..... | 4 |
| Body..... | 4 |
| Key Research Accomplishments..... | 5 |
| Reportable Outcomes..... | 5 |
| Conclusions..... | 5 |
| References..... | 5 |
| Appendices..... | 5 |

Introduction

This laboratory has shown that the protease Plasmin enzymatically produces an Osteocalcin-derived C-terminal Hexapeptide from bone matrix [1]. This hexapeptide promotes the growth of human osteosarcoma cells by blocking the action of the hormone oxytocin [2].

We hypothesize that by the same mechanism C-terminal Hexapeptide promotes the growth of breast cancer cells in bone.

Rationale: Osteocalcin, an abundant protein of the bone matrix, is metabolized to form two peptides, the carboxy-terminal hexapeptide (RFYGPV) called "C-terminal Hexapeptide" and an amino terminal "N-mid peptide" [1]. We have proven that the C-terminal Hexapeptide and N-mid peptide are formed by Plasmin proteolysis [1]. Plasmin is postulated to be involved in tumor metastasis due to the presence of plasminogen activators on the tumor cell surface [2]. The N-mid peptide is the most abundant metabolite of human Osteocalcin [3]. In the same metabolic cleavage, the C-terminal Hexapeptide is constantly being made as a normal metabolite of Osteocalcin. We have proven that the C-terminal Hexapeptide is growth stimulatory for osteosarcoma cells, perhaps mediating the growth of osteosarcoma within the bone [2]. The C-terminal Hexapeptide blocks oxytocin action [2]. Human breast cancer cells that are growth inhibited by oxytocin [4,5] may be growth stimulated in bone where abundant C-terminal Hexapeptide is present. Growth stimulation in bone would enhance the likelihood of bone metastasis by breast cancer cells.

Counteracting the metastasis of breast cancer to bone could enhance patient survival. Understanding the mechanisms that enable breast cancer cells to metastasize, survive, and grow in bone are vital to alter the process. It may be possible to develop strategies to inhibit C-terminal Hexapeptide growth enhancement to block metastasis of breast cancer to bone.

Body

The initial objective was to determine the affect of C-terminal Hexapeptide (available as synthetic peptide) on breast cancer cell growth that was inhibited by oxytocin. Initial experiments were to establish culture conditions to reproduce previous results [4,5]. Cultured human breast carcinoma cells (MDA-MB-231 from American Type Culture Collection) were tested for growth effects by adding oxytocin and assessing the effect on growth by the ATCC MTT colorimetric assay. The effect of cell number and serum concentration on the growth inhibitory effect of oxytocin were determined. 1×10^{-5} M oxytocin inhibited growth of MDA-MB-231 only in the presence of 2% serum not 10% serum. Previously, 1×10^{-7} M has been published as an effective dose [4,5]. We have tried different batches and forms of oxytocin to determine whether there is a more active form for our studies. These efforts are ongoing. We are establishing an assay for cAMP and/or PGE_2 as well as growth to assess the effectiveness of oxytocin on the cells. We have been granted a one-year no cost extension to continue our studies.

Key Research Accomplishments

[1] After a short delay a half-time technician has been trained for culture experiments and growth assays. The laboratory was not previously culturing cells or performing growth assays, but is now competent in both techniques.

[2] The activity of oxytocin preparations has been discovered to vary with type and purity. The laboratory is still searching for a reliable source of oxytocin, and is developing methods to assess activity prior to committing to time-consuming growth curve experiments.

Reportable Outcomes

More time is required to develop a reportable outcome. We will report a summary of our previous findings with osteosarcoma cells and up to date results at the Era of Hope meeting on September 25-28 2002 in an abstract entitled "Regulation of cancer cell growth by C-terminal hexapeptide derived from osteocalcin". We have to reproduce the previously published oxytocin effects before we can move on with studies with the C-terminal peptide.

Conclusions

Our experiments have been inconclusive, although the growth assay is working well with very good reproducibility. We suspect the source of oxytocin and/or its stability may be the cause of results which are two orders of magnitude different than previously published results.

References

1. Novak, JF, Hayes, JC, and Nishimoto, SK. Plasmin-mediated proteolysis of Osteocalcin. *J. Bone and Mineral Research* 12, 1035-1042, 1997
2. Novak, JF, Judkins, M, Chernin, M, Cassoni, P, Bussolati, G, Niche, J, & Nishimoto, SK. A plasmin-derived hexapeptide . . of Osteocalcin counteracts oxytocin growth inhibition of osteosarcoma. *Cancer Research* 60:3470-3476, 2000.
3. Garnero, P, Grimaux, M, Seguin, P, and Delmas, PD. Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro. *J. Bone and Mineral Research* 9, 255-264, 1994
4. Cassoni, P, Sapino, A, Fortunati, N, Munaron, L, Chini, B, and Bussolati, G. Oxytocin inhibits the proliferation of MDA-MB231 human breast-cancer cells via cAMP and protein kinase A. *Int. J. Cancer*, 72, 340-344, 1997
5. Cassoni, P, Sapino, A, Negro, F, and Bussolati, G. Oxytocin inhibits the proliferation of human breast cancer cell lines. *Virchows Arch*, 425, 467-472, 1994

Appendix

none